                         SEQUENCE LISTING

<110>  Fred Hutchinson Cancer Research Center
 
<120>  PROTECTIVE ANTIBODIES AGAINST RESPIRATORY VIRAL INFECTIONS

<130>  F053-0125PCT / 20-139-WO-PCT

<150>  US 63/154,166
<151>  2021-02-26

<160>  194   

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-E12 CDRH1

<400>  1

Gly Phe Thr Phe Ser Asp His Tyr 
1               5               


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-E12 CDRH2

<400>  2

Ile Ser Ser Ser Gly Ser Asn Thr 
1               5               


<210>  3
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-E12 CDRH3

<400>  3

Ala Arg Ala Lys Trp Gly Thr Met Gly Arg Gly Ala Pro Pro Thr Ile 
1               5                   10                  15      


Tyr Asp His 
            


<210>  4
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-E12 CDRL1

<400>  4

Gln Ser Leu Leu Gln Ser Asn Gly Asn Asn Tyr 
1               5                   10      


<210>  5
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-E12 CDRL3

<400>  5

Met Gln Ala Leu Gln Thr Pro Leu Thr 
1               5                   


<210>  6
<211>  378
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-E12 variable heavy chain

<400>  6
caggtgcagc tgttggagtc tgggggaaag ttggtcaagc ctggagggtc cctgagactc       60

tcctgtgcag cctctggatt caccttcagt gaccactaca tgatctggat ccgccaggct      120

cccgggaagg ggctggagtg gatttcatac ataagtagta gtggtagtaa cacaatctac      180

gcagactctt tgatgggccg attcaccatc tccagagaca acgccaagaa ctctctgtat      240

ctacaaatga acagcctgag gaccgaggac acggccgttt attactgtgc gagagcaaag      300

tggggtacta tgggtcgggg agcacccccg acaatttatg accactgggg ccagggaacc      360

ctggtcaccg tctcctca                                                    378


<210>  7
<211>  337
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-E12 variable kappa light chain

<400>  7
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc       60

atctcctgta ggtctagtca gagcctcctg caaagtaatg gaaacaatta tttggagtgg      120

tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttc caatcgggcc      180

tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaagatc      240

agcagagtgg aggctgagga tgctggggtt tattactgca tgcaagctct acaaactccg      300

ctcactttcg gcggagggac caaggtggag atcaaac                               337


<210>  8
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A3 CDRH1

<400>  8

Gly Phe Thr Phe Ser Asn Tyr Trp 
1               5               


<210>  9
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A3 CDRH2

<400>  9

Val Lys Glu Glu Gly Ser Glu Lys 
1               5               


<210>  10
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A3 CDRH3

<400>  10

Ala Gly Glu Val Lys Ser Gly Trp Phe Gly Arg Tyr Phe Asp Ser 
1               5                   10                  15  


<210>  11
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A3 CDRL1

<400>  11

Gln Ser Val Gly Ser Trp 
1               5       


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A3 CDRL3

<400>  12

Gln Gln Tyr Ser Ser Phe Pro Tyr Thr 
1               5                   


<210>  13
<211>  367
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-A3 antibody variable heavy chain

<400>  13
gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc       60

tcctgtacag cctctggatt cacctttagc aattattgga tgagctgggt ccgccaggct      120

ccagggaagg ggctggagtg ggtggccaat gtgaaggaag aaggaagtga gaaacactat      180

gtagactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcagtgtat      240

ctgcagatga gcagcctgag agccgaggac acggctgtct attactgtgc gggagaggtt      300

aagagtggct ggttcggtcg gtactttgac tcctggggcc agggaaccct ggtcaccgtc      360

tcctcag                                                                367


<210>  14
<211>  322
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-A3 antibody variable kappa light chain

<400>  14
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgttggaga cagagtcacc       60

atcaattgcc gggccagtca gagtgttggt agctggttgg cctggtatca gcagaaacca      120

gggaaagccc ctaagctcct gatgtataag acatctactt tacaaagagg ggtcccatca      180

aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct      240

gatgattttg cagcttatta ctgccaacag tatagtagtt ttccgtacac ttttggccag      300

gggaccaagc tggagatcaa ac                                               322


<210>  15
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-B5 CDRH1

<400>  15

Gly Tyr Asn Phe Thr Asn Tyr Trp 
1               5               


<210>  16
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-B5 CDRH2

<400>  16

Ile Tyr Pro Ala Asp Ser Asp Thr 
1               5               


<210>  17
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-B5 CDRH3

<400>  17

Ala Arg Pro Ser Thr Arg Trp Phe Val Pro Gly Gly Met Asp Val 
1               5                   10                  15  


<210>  18
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-B5 CDRL1

<400>  18

Gln Ser Ile Gly Ala Trp 
1               5       


<210>  19
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-B5 CDRL3

<400>  19

Gln Gln His Ser Ser Tyr Pro Ser Thr 
1               5                   


<210>  20
<211>  366
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-B5 variable heavy chain

<400>  20
gaggtgcagc tggtgcagtc tggagcagag gtgaaaaagc ccggggagtc tctgaggatc       60

tcctgtaagg gttctggata caactttacc aactactgga tcgcctgggt gcgccagatg      120

cccgggaaag gcctggagtg gatggggatc atctatcctg ctgactcgga taccagatac      180

agcccgtcct tccaaggcca agtcaccatc tcagccgaca agtccatcac caccgcctac      240

ctgcagtgga gcagcctgaa ggcctcggac accgccatat actactgtgc gagaccgagt      300

actaggtggt tcgtccctgg cggtatggac gtctggggcc aaggcaccac ggtcatcgtc      360

tcctca                                                                 366


<210>  21
<211>  322
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-B5 variable kappa light chain

<400>  21
gacatccaga tgacccagtc tccttccacc ctgtctgctt ctgtaggaga cagagtcacc       60

atttcttgcc gggccactca gagtattggt gcctggttgg cctggtatca gcagaaacca      120

ggggaacccc ctaagctcct gatctataag gcgtctactt tagagagtgg ggtcccatca      180

aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct      240

gatgattctg caacttatta ctgccaacag catagtagtt atccttctac tttcggcgga      300

gggaccaagg tggagatcaa ac                                               322


<210>  22
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A10 CDRH1

<400>  22

Gly Phe Asn Phe Asn Asn Tyr Gly 
1               5               


<210>  23
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A10 CDRH2

<400>  23

Val Ser Phe Asp Gly Ser Asn Arg 
1               5               


<210>  24
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A10 CDRH3

<400>  24

Ser Lys Ser Lys Tyr Ser Asp Phe Trp Ser Glu Ile 
1               5                   10          


<210>  25
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A10 CDRL1

<400>  25

Gln Asn Val Met Arg Tyr 
1               5       


<210>  26
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A10 CDRL3

<400>  26

Gln Gln Arg Thr Asn His Arg Phe Ser 
1               5                   


<210>  27
<211>  358
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-A10 variable heavy chain

<400>  27
caggtgcagc tggtggagtc tgggggaggc gtggtccggc ctgggaggtc cctgagactc       60

tcctgtgtag cctctggatt caacttcaat aactatgggc tgcagtggat ccgccaggct      120

ccaggcaagg ggctggagtg ggtggcaggt gtctcgtttg atgggagtaa tagatattat      180

gcagactccg tgaagggccg agtcaccata tccagagacg attccaagaa caccctgtat      240

ctagaaatga acagcctgag agctgaggac acaggaatat attactgttc gaagtccaag      300

tactccgact tttggagcga aatatggggc cagggaaccc tggtcaccgt ctcctcag        358


<210>  28
<211>  322
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-A10 variable kappa light chain

<400>  28
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc       60

ctctcctgca gggccagtca gaatgttatg aggtacttag cctggtacca acagagacct      120

ggccaggctc ccagactcct cttctatgat gcatccagcc gggccactgg catcccagcc      180

cggttcactg ccagtgggtc tgggacagac ttcactctca ccatcagcgg cctcgagcct      240

ggagattttg cagtttatta ctgtcagcag cgtaccaacc atagattctc tttcggccct      300

gggaccaagg tggatatcaa ac                                               322


<210>  29
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A12 CDRH1

<400>  29

Gly Asp Ser Val Lys Ser Asp Asp Phe Tyr 
1               5                   10  


<210>  30
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A12 CDRH2

<400>  30

Ile Tyr Tyr Gly Gly Arg Thr 
1               5           


<210>  31
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A12 CDRH3

<400>  31

Val Arg Val Glu Gly Leu Leu Trp Phe Gly Glu Leu Phe Asp Tyr 
1               5                   10                  15  


<210>  32
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A12 CDRL1

<400>  32

Asn Ser Asn Ile Gly Asn Asn Phe 
1               5               


<210>  33
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A12 CDRL3

<400>  33

Ala Ala Trp Gln Asp Gly Leu Ser Gly Pro Leu 
1               5                   10      


<210>  34
<211>  370
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-A12 variable heavy chain

<400>  34
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcagagac cctgtccctc       60

acttgcactg tctctggtga ctccgtcaag agtgatgatt tctactggag ttggatccgg      120

cagcccccag ggaagggcct ggagtggatt ggcttcatct attacggtgg cagaacttac      180

tacaacccgt ccctcagtgg tcgaggaacc atttcagtgg acacgtccaa gaaccacttc      240

ttcctggagc tgacctctgt gactgccgca gacacggccg tatactactg tgtcagggtc      300

gaaggattac tgtggttcgg ggagttattc gactactggg gccagggaac cctggtcacc      360

gtctcctcag                                                             370


<210>  35
<211>  331
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PI3-A12 variable lambda light chain

<400>  35
cagtctgtgc tgacgcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc       60

tcttgttctg gaagcaactc caacatcgga aataattttg tctactggta ccaacaagtc      120

ccaggatcgg cccccaaagt cgtcatttac aaggattatc agcgcccctc aggggtccct      180

gaccgattct ctgcctccaa gtctggcacc tcagcctccc tgaccatcag cgggctccgg      240

tccgacgatg aggcccatta ttactgtgca gcatggcagg acggtctgag tgggccgtta      300

tttggcggag ggaccaagct gaccgtccta g                                     331


<210>  36
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb 3x1 CDRH1

<400>  36

Gly Phe Thr Phe Ser Ser Phe Gly 
1               5               


<210>  37
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb 3x1 CDRH2

<400>  37

Ile Ser His Ser Ala Gly Phe Leu 
1               5               


<210>  38
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb 3x1 CDRH3

<400>  38

Ala Lys Arg Leu Ala Gly Leu Pro Asp Leu Glu Trp Leu Leu Tyr Pro 
1               5                   10                  15      


Asn Phe Leu Asp His 
            20      


<210>  39
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb 3x1 CDRL1

<400>  39

Ile Leu Arg Thr Tyr Tyr 
1               5       


<210>  40
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb 3x1 CDRL3

<400>  40

Ser Ser Arg Asp Arg Ser Gly Asn His Val Leu 
1               5                   10      


<210>  41
<211>  385
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  3x1 xnAb variable heavy chain

<400>  41
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggtgggtc cctgagactg       60

tcttgtgcgg cctcaggatt cacctttagc agctttggca tgagctgggt ccgccaatct      120

ccaggaaagg ggctggagtg ggtcgcagat ataagccata gtgctggctt cttaaactac      180

gcagactccg tgaagggccg gttcaccgtc tccagagaca attctaagag cacgctgcat      240

ctccaaatga agagcctgag agccgaggac acggccgtat attactgtgc gaaaagactt      300

gccggattac cagatttgga gtggttactt taccctaact tcttagacca ctggggccag      360

ggaaccctgg tcaccgtctc ctcag                                            385


<210>  42
<211>  325
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  3x1 xnAb variable lambda light chain

<400>  42
tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc       60

acatgccaag gagacatact gagaacctat tatgtaagct ggtaccagca gaaaccagga      120

caggccccgc tacttgtcat ctatggtaaa aacaaccgac cctcagtgat cccagaccga      180

ttctctggct ccacctcagg agacacagct tccttgacca tcactggggc tcaggcggaa      240

gatgaggctg agtattattg tagctctcgg gacaggagtg gaaaccatgt gctattcggc      300

ggagggacca agctgaccgt cctag                                            325


<210>  43
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-B11 CDRH1

<400>  43

Gly Phe Pro Phe Ser Ser Tyr Lys 
1               5               


<210>  44
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-B11 CDRH2

<400>  44

Ile Ser Ala Ser Gly Ser Tyr Ile 
1               5               


<210>  45
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-B11 CDRH3

<400>  45

Ala Arg Asp Gly Gly Arg Glu Leu Ser Pro Phe Glu Lys 
1               5                   10              


<210>  46
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-B11 CDRL1

<400>  46

Asn Ser Asn Ile Gly Thr Gly Tyr Asp 
1               5                   


<210>  47
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-B11 CDRL3

<400>  47

Gln Ser Tyr Asp Lys Ser Leu Gly Gly Trp Val 
1               5                   10      


<210>  48
<211>  361
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MxR-B11 variable heavy chain

<400>  48
gaggtgcagg tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc       60

tcctgtgcag cctctggatt ccccttcagt tcttataaga tggactgggt ccgccaggct      120

ccagggaagg ggctggagtg ggtctcgtcc atcagtgcta gtggaagtta cataaactat      180

gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat      240

ctgcaaatga aaagcctgag agccgacgac acggctgtat atttttgtgc gagagacggc      300

ggaagagaac tgagcccctt tgaaaagtgg ggccagggaa tcctggtcac cgtctcctca      360

g                                                                      361


<210>  49
<211>  334
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MxR-B11 variable light chain

<400>  49
cagtctgtgc tgacgcagcc gccctcagtg tctggggccc caggacagag ggtcaccatc       60

tcctgcactg ggaccaactc caacatcggg acaggttatg atgtacactg gtaccagcag      120

cttccgggaa cagcccccaa agtcgtcctc tttgataaca acaatcggcc ctcaggggtc      180

cctgaccgat tctctggctc caagtctggc acttcagccg ccctggccat cactggcctc      240

caggctgagg atgaggctgt ttattactgc cagtcctatg acaagagcct gggtggttgg      300

gtgttcggcg gagggaccaa gctgaccgtc ctag                                  334


<210>  50
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-D10 CDRH1

<400>  50

Gly Phe Ile Phe Ser Asn Tyr Asp 
1               5               


<210>  51
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-D10 CDRH2

<400>  51

Ile Thr Gly Gly Ser Ser Phe Ile 
1               5               


<210>  52
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-D10 CDRH3

<400>  52

Ala Arg Asp Gly Gly Arg Gln Leu Ser Pro Cys Glu His 
1               5                   10              


<210>  53
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-D10 CDRL1

<400>  53

Ser Ser Asn Ile Gly Ala Gly Tyr Asp 
1               5                   


<210>  54
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-D10 CDRL3

<400>  54

Gln Ser Tyr Asp Arg Gly Leu Ser Gly Trp Ala 
1               5                   10      


<210>  55
<211>  361
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MxR-D10 variable heavy chain

<400>  55
gaggtgcagg tggtggagtc ggggggaggc ctggtcaagc ctggggggtc cctgagactc       60

tcctgtacag cctctggatt catattcagt aattatgaca tgaactgggt ccgccaggct      120

ccagggaagg gcctggagtg ggtcgcctcc attactggtg gtagtagttt cataaattac      180

gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa gtcactgtat      240

ctgcaaatga acagcctcag agccgaggac acggctgtct attactgtgc gagagatggc      300

gggagacagt tgagtccgtg tgaacattgg ggccagggaa ccctggtcac cgtctcctca      360

g                                                                      361


<210>  56
<211>  334
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  MxR-D10 variable light chain

<400>  56
cagtctgtgc tgacgcagcc gccctcagtg tctgggtccc cagggcagag ggtcaccatc       60

tcctgcactg ggggcagctc caacatcggg gcaggttatg atgtacactg gtaccaacaa      120

cttccaggat cagcccccaa actcctcatg tatgatagta ataatcgacc ctcaggggtc      180

cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc      240

caggctgagg atgaggctga ttattactgc cagtcctatg acaggggcct gagtgggtgg      300

gcgttcggcg gagggaccaa gctgaccgtc ctgg                                  334


<210>  57
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH1

<400>  57

Glu Phe Thr Phe Asn Thr Tyr Gly 
1               5               


<210>  58
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH2

<400>  58

Ile Ser Tyr Asp Gly Thr Lys Lys 
1               5               


<210>  59
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH3

<400>  59

Ala Arg Ser Gly Asp Ser Asp Ala Phe Asp Ile 
1               5                   10      


<210>  60
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL1

<400>  60

Glu Leu Gly Asp Lys Phe 
1               5       


<210>  61
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL3

<400>  61

Gln Ala Trp Asp Ser Asn Ser Tyr Val 
1               5                   


<210>  62
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH1

<400>  62

Gly Gly Thr Phe Gly Ser Tyr Ala 
1               5               


<210>  63
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH2

<400>  63

Ile Asp Ala Ala Asn Gly Asn Thr 
1               5               


<210>  64
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH3

<400>  64

Ala Arg Asp Arg Trp Met Thr Thr Arg Ala Phe Asp Ile 
1               5                   10              


<210>  65
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL1

<400>  65

Ser Ser Asn Ile Gly Ser Asn Tyr 
1               5               


<210>  66
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL3

<400>  66

Ala Ala Trp Asp Asp Ser Leu Arg Gly Pro Val 
1               5                   10      


<210>  67
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OKT3 CDRL1

<400>  67

Ser Ala Ser Ser Ser Val Ser Tyr Met Asn 
1               5                   10  


<210>  68
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OKT3 CDRL2

<400>  68

Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser 
1               5                   10      


<210>  69
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OKT3 CDRL3

<400>  69

Gln Gln Trp Ser Ser Asn Pro Phe Thr 
1               5                   


<210>  70
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OKT3 CDRH1

<400>  70

Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His 
1               5                   10              


<210>  71
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OKT3 CDRH2

<400>  71

Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp 
1               5                   10                  15      


<210>  72
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OKT3 CDRH3

<400>  72

Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr 
1               5                   10  


<210>  73
<211>  242
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 scFv

<400>  73

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr 
            20                  25                  30          


Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Leu Thr Val Ser Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 
        115                 120                 125             


Gly Ser Gly Gly Gly Gly Ser Gln Ile Val Leu Thr Gln Ser Pro Ala 
    130                 135                 140                 


Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala 
145                 150                 155                 160 


Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr 
                165                 170                 175     


Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val 
            180                 185                 190         


Pro Ala His Phe Arg Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr 
        195                 200                 205             


Ile Ser Gly Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln 
    210                 215                 220                 


Trp Ser Ser Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
225                 230                 235                 240 


Asn Arg 
        


<210>  74
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRL1

<400>  74

Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  75
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRL3

<400>  75

Gly Gln Gly Thr Gln Tyr Pro Phe Thr 
1               5                   


<210>  76
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH1

<400>  76

Gly Phe Thr Phe Thr Lys Ala Trp 
1               5               


<210>  77
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH2

<400>  77

Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr 
1               5                   10  


<210>  78
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH3

<400>  78

Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr 
1               5                   10          


<210>  79
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRL1

<400>  79

Gln Ser Leu Val His Asp Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  80
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH1

<400>  80

Gly Phe Thr Phe Ser Asn Ala Trp 
1               5               


<210>  81
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH2

<400>  81

Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr 
1               5                   10  


<210>  82
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH3

<400>  82

Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr 
1               5                   10          


<210>  83
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRL1

<400>  83

Gln Ser Leu Glu His Asn Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  84
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH2

<400>  84

Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr 
1               5                   10  


<210>  85
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH3

<400>  85

Arg Tyr Val His Tyr Gly Ile Gly Tyr Ala Met Asp Ala 
1               5                   10              


<210>  86
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRL1

<400>  86

Gln Ser Leu Val His Thr Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  87
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRL3

<400>  87

Gly Gln Gly Thr His Tyr Pro Phe Thr 
1               5                   


<210>  88
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH1

<400>  88

Gly Phe Thr Phe Thr Asn Ala Trp 
1               5               


<210>  89
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH2

<400>  89

Lys Asp Lys Ser Asn Asn Tyr Ala Thr 
1               5                   


<210>  90
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD3 CDRH3

<400>  90

Arg Tyr Val His Tyr Arg Phe Ala Tyr Ala Leu Asp Ala 
1               5                   10              


<210>  91
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  variable heavy chain of TGN1412

<400>  91

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Cys Ile Tyr Pro Gly Asn Val Asn Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Asp Arg Ala Thr Leu Thr Val Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Thr Arg Ser His Tyr Gly Leu Asp Trp Asn Phe Asp Val Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  92
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  variable light chain of TGN1412

<400>  92

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Tyr Val Trp 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Thr Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  93
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD28 CDRL1

<400>  93

His Ala Ser Gln Asn Ile Tyr Val Trp Leu Asn 
1               5                   10      


<210>  94
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD28 CDRL2

<400>  94

Lys Ala Ser Asn Leu His Thr 
1               5           


<210>  95
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD28 CDRL3

<400>  95

Gln Gln Gly Gln Thr Tyr Pro Tyr Thr 
1               5                   


<210>  96
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD28 CDRH1

<400>  96

Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His 
1               5                   10  


<210>  97
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD28 CDRH2

<400>  97

Cys Ile Tyr Pro Gly Asn Val Asn Thr Asn Tyr Asn Glu Lys 
1               5                   10                  


<210>  98
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD28 CDRH3

<400>  98

Ser His Tyr Gly Leu Asp Trp Asn Phe Asp Val 
1               5                   10      


<210>  99
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD28 CDRH1

<400>  99

Ser Tyr Tyr Ile His 
1               5   


<210>  100
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD28 CDRH2

<400>  100

Cys Ile Tyr Pro Gly Asn Val Asn Thr Asn Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  101
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRL1

<400>  101

Arg Ala Ser Gln Ser Val Ser 
1               5           


<210>  102
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRL2

<400>  102

Ala Ser Asn Arg Ala Thr 
1               5       


<210>  103
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRL3

<400>  103

Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr 
1               5                   10  


<210>  104
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRH1

<400>  104

Tyr Tyr Trp Ser 
1               


<210>  105
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRH3

<400>  105

Tyr Gly Pro Gly Asn Tyr Asp Trp Tyr Phe Asp Leu 
1               5                   10          


<210>  106
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRL1

<400>  106

Ser Gly Asp Asn Ile Gly Asp Gln Tyr Ala His 
1               5                   10      


<210>  107
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRL2

<400>  107

Gln Asp Lys Asn Arg Pro Ser 
1               5           


<210>  108
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRL3

<400>  108

Ala Thr Tyr Thr Gly Phe Gly Ser Leu Ala Val 
1               5                   10      


<210>  109
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRH1

<400>  109

Gly Tyr Ser Phe Ser Thr Tyr Trp Ile Ser 
1               5                   10  


<210>  110
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRH2

<400>  110

Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser 
1               5                   10                  


<210>  111
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-4-1BB CDRH3

<400>  111

Gly Tyr Gly Ile Phe Asp Tyr 
1               5           


<210>  112
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD8 CDRL1

<400>  112

Arg Thr Ser Arg Ser Ile Ser Gln Tyr Leu Ala 
1               5                   10      


<210>  113
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD8 CDRL2

<400>  113

Ser Gly Ser Thr Leu Gln Ser 
1               5           


<210>  114
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD8 CDRL3

<400>  114

Gln Gln His Asn Glu Asn Pro Leu Thr 
1               5                   


<210>  115
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD8 CDRH1

<400>  115

Gly Phe Asn Ile Lys Asp 
1               5       


<210>  116
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD8 CDRH2

<400>  116

Arg Ile Asp Pro Ala Asn Asp Asn Thr 
1               5                   


<210>  117
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CD8 CDRH3

<400>  117

Gly Tyr Gly Tyr Tyr Val Phe Asp His 
1               5                   


<210>  118
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-KIR2DL1 and KIR2DL2/3 variable light chain

<400>  118

Glu Ile Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Met Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr 
            100                 105                 


<210>  119
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-KIR2DL1 and KIR2DL2/3 variable heavy chain

<400>  119

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Phe Tyr 
            20                  25                  30          


Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Ile Pro Ile Phe Gly Ala Ala Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ile Pro Ser Gly Ser Tyr Tyr Tyr Asp Tyr Asp Met Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  120

<400>  120
000

<210>  121
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker


<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  (GlyGlyGlyGlySer) is repeated n times wherein n is an integer of 
       1, 2, 3, 4, 5, 6, 7, 8, 9 or 10

<400>  121

Gly Gly Gly Gly Ser 
1               5   


<210>  122
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker


<220>
<221>  MISC_FEATURE
<222>  (1)..(4)
<223>  (GlyGlyGlySer) is repeated n times wherein n is an integer of 1, 
       2, 3, 4, 5, 6, 7, 8, 9 or 10

<220>
<221>  MISC_FEATURE
<222>  (5)..(9)
<223>  (GlyGlyGlyGlySer) is repeated n times wherein n is an integer of 
       1, 2, 3, 4, 5, 6, 7, 8, 9 or 10

<400>  122

Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   


<210>  123
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker


<220>
<221>  MISC_FEATURE
<222>  (1)..(4)
<223>  (GlyGlyGlySer) is repeated n times wherein n is an integer of 1, 
       2, 3, 4, 5, 6, 7, 8, 9 or 10

<220>
<221>  MISC_FEATURE
<222>  (5)..(7)
<223>  (GlyGlySer) is repeated n times wherein n is an integer of 1, 2, 
       3, 4, 5, 6, 7, 8, 9 or 10

<400>  123

Gly Gly Gly Ser Gly Gly Ser 
1               5           


<210>  124
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker


<220>
<221>  MISC_FEATURE
<222>  (1)..(4)
<223>  (GlyGlyGlySer) is repeated n times wherein n is an integer of 1, 
       2, 3, 4, 5, 6, 7, 8, 9 or 10

<400>  124

Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   


<210>  125
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
1               5                   10                  15      


Gly Gly Gly Ser 
            20  


<210>  126
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  126

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  127
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  127

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10  


<210>  128
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  128

Gly Gly Gly Gly Ser 
1               5   


<210>  129
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  129

Gly Gly Gly Ser Gly Gly Gly Ser 
1               5               


<210>  130
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  130

Gly Gly Gly Ser 
1               


<210>  131
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  131

Gly Gly Ser Gly Gly Ser 
1               5       


<210>  132
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  132

Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Gly 
1               5                   10      


<210>  133
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  133

Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly 
1               5                   10  


<210>  134
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GlySer linker

<400>  134

Gly Gly Ser Gly Gly Gly Ser Gly 
1               5               


<210>  135
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH1

<400>  135

Gly Gly Thr Phe Ser Ser Tyr Ala 
1               5               


<210>  136
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH2

<400>  136

Ile Ile Pro Ile Phe Gly Lys Ala 
1               5               


<210>  137
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH3

<400>  137

Ala Arg Asp Gln Gly Ile Ser Ala Asn Phe Lys Asp Ala Phe Asp Ile 
1               5                   10                  15      


<210>  138
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL1

<400>  138

Glu Ser Val Gly Ser Asn 
1               5       


<210>  139
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL3

<400>  139

Gln Gln Tyr Asn Asn Trp Pro Leu Thr 
1               5                   


<210>  140

<400>  140
000

<210>  141
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH2

<400>  141

Ile Ile Pro Ile Phe Gly Thr Ala 
1               5               


<210>  142
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH3

<400>  142

Ala Arg Val Gly Tyr Cys Ser Ser Thr Ser Cys His Ile Gly Ala Phe 
1               5                   10                  15      


Asp Ile 
        


<210>  143
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL1

<400>  143

Gln Ser Val Ser Ser Ser 
1               5       


<210>  144
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL3

<400>  144

Gln Gln Tyr Ser Ser Ser Pro Tyr Thr 
1               5                   


<210>  145

<400>  145
000

<210>  146

<400>  146
000

<210>  147
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH3

<400>  147

Ala Arg Ala Ser Tyr Cys Ser Thr Thr Ser Cys Ala Ser Gly Ala Phe 
1               5                   10                  15      


Asp Ile 
        


<210>  148
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL1

<400>  148

Gln Ser Val Leu Tyr Ser Ser Asn Asn Asn Tyr 
1               5                   10      


<210>  149
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL3

<400>  149

Gln Gln Tyr Tyr Ser Val Pro Phe Thr 
1               5                   


<210>  150
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH1

<400>  150

Gly Tyr Thr Phe Asn Val Tyr Ala 
1               5               


<210>  151
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH2

<400>  151

Ile Ile Pro Ile Leu Gly Ile Ala 
1               5               


<210>  152
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH3

<400>  152

Ala Arg Asp Tyr Tyr Gly Ser Gly Ala Arg Gly Phe Asp Tyr 
1               5                   10                  


<210>  153
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL1

<400>  153

Ser Asn Asn Val Gly Asn Gln Gly 
1               5               


<210>  154
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL3

<400>  154

Ala Ser Trp Asp Ser Ser Leu Ser Val Trp Val 
1               5                   10      


<210>  155

<400>  155
000

<210>  156
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH2

<400>  156

Ile Ile Pro Ile Phe Gly Ile Ala 
1               5               


<210>  157
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRH3

<400>  157

Ala Ser Ser Asn Tyr Tyr Gly Ser Gly Ser Tyr Tyr Pro Arg Ser Ala 
1               5                   10                  15      


Phe Asp Ile 
            


<210>  158
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL1

<400>  158

Gln Ser Ile Ser Asn Asp 
1               5       


<210>  159
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-MERS-CoV CDRL3

<400>  159

Gln Gln Tyr Gly Val Ser Pro Leu Thr 
1               5                   


<210>  160
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-SARS-CoV variable heavy chain

<400>  160

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Val Gly Arg Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val 
    


<210>  161
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-SARS-CoV variable light chain

<400>  161

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asp 
            20                  25                  30          


Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  162
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-SARS-CoV variable heavy chain

<400>  162

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Val Gly Arg Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  163

<400>  163
000

<210>  164
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-SARS-CoV variable heavy chain

<400>  164

Gln Val His Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Val His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Gly Gly Arg Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  165
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-SARS-CoV variable light chain

<400>  165

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp 
            20                  25                  30          


Leu Gly Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Arg Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Asn Ser Tyr Pro Ile 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 
            100                 105         


<210>  166
<211>  126
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PI3-E12 heavy chain

<400>  166

Gln Val Gln Leu Leu Glu Ser Gly Gly Lys Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His 
            20                  25                  30          


Tyr Met Ile Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Ser Tyr Ile Ser Ser Ser Gly Ser Asn Thr Ile Tyr Ala Asp Ser Leu 
    50                  55                  60                  


Met Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ala Lys Trp Gly Thr Met Gly Arg Gly Ala Pro Pro Thr Ile 
            100                 105                 110         


Tyr Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 125     


<210>  167
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PI3-E12 light chain

<400>  167

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser 
            20                  25                  30          


Asn Gly Asn Asn Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Ala Gly Val Tyr Tyr Cys Met Gln Ala 
                85                  90                  95      


Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  168
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A3 heavy chain

<400>  168

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asn Val Lys Glu Glu Gly Ser Glu Lys His Tyr Val Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Val Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Glu Val Lys Ser Gly Trp Phe Gly Arg Tyr Phe Asp Ser Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  169
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A3 light chain

<400>  169

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Gly Ser Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Met 
        35                  40                  45              


Tyr Lys Thr Ser Thr Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Asp Asp Phe Ala Ala Tyr Tyr Cys Gln Gln Tyr Ser Ser Phe Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  170
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-B5 heavy chain

<400>  170

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Asn Phe Thr Asn Tyr 
            20                  25                  30          


Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Ile Ile Tyr Pro Ala Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Thr Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Pro Ser Thr Arg Trp Phe Val Pro Gly Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Ile Val Ser Ser 
        115                 120         


<210>  171
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-B5 light chain

<400>  171

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Arg Ala Thr Gln Ser Ile Gly Ala Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Lys Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Asp Asp Ser Ala Thr Tyr Tyr Cys Gln Gln His Ser Ser Tyr Pro Ser 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  172
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A10 heavy chain

<400>  172

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Asn Phe Asn Asn Tyr 
            20                  25                  30          


Gly Leu Gln Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gly Val Ser Phe Asp Gly Ser Asn Arg Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Val Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys 
                85                  90                  95      


Ser Lys Ser Lys Tyr Ser Asp Phe Trp Ser Glu Ile Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  173
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A10 light chain

<400>  173

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Val Met Arg Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Phe 
        35                  40                  45              


Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Ala Arg Phe Thr Ala 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu Pro 
65                  70                  75                  80  


Gly Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Thr Asn His Arg Phe 
                85                  90                  95      


Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
            100                 105         


<210>  174
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A12 heavy chain

<400>  174

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Val Lys Ser Asp 
            20                  25                  30          


Asp Phe Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Phe Ile Tyr Tyr Gly Gly Arg Thr Tyr Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Ser Gly Arg Gly Thr Ile Ser Val Asp Thr Ser Lys Asn His Phe 
65                  70                  75                  80  


Phe Leu Glu Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Val Arg Val Glu Gly Leu Leu Trp Phe Gly Glu Leu Phe Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120             


<210>  175
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb PI3-A12 light chain

<400>  175

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn 
            20                  25                  30          


Phe Val Tyr Trp Tyr Gln Gln Val Pro Gly Ser Ala Pro Lys Val Val 
        35                  40                  45              


Ile Tyr Lys Asp Tyr Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Ala Ser Lys Ser Gly Thr Ser Ala Ser Leu Thr Ile Ser Gly Leu Arg 
65                  70                  75                  80  


Ser Asp Asp Glu Ala His Tyr Tyr Cys Ala Ala Trp Gln Asp Gly Leu 
                85                  90                  95      


Ser Gly Pro Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  176
<211>  128
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb 3x1 heavy chain

<400>  176

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asp Ile Ser His Ser Ala Gly Phe Leu Asn Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Ser Thr Leu His 
65                  70                  75                  80  


Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Arg Leu Ala Gly Leu Pro Asp Leu Glu Trp Leu Leu Tyr Pro 
            100                 105                 110         


Asn Phe Leu Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 125             


<210>  177
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb 3x1 light chain

<400>  177

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ile Leu Arg Thr Tyr Tyr Val 
            20                  25                  30          


Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Leu Leu Val Ile Tyr 
        35                  40                  45              


Gly Lys Asn Asn Arg Pro Ser Val Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Thr Ser Gly Asp Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 
65                  70                  75                  80  


Asp Glu Ala Glu Tyr Tyr Cys Ser Ser Arg Asp Arg Ser Gly Asn His 
                85                  90                  95      


Val Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105             


<210>  178
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MxR-B11 variable heavy chain

<400>  178

Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Ser Tyr 
            20                  25                  30          


Lys Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Ser Ala Ser Gly Ser Tyr Ile Asn Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Lys Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Asp Gly Gly Arg Glu Leu Ser Pro Phe Glu Lys Trp Gly Gln 
            100                 105                 110         


Gly Ile Leu Val Thr Val Ser Ser 
        115                 120 


<210>  179
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MxR-B11 variable light chain

<400>  179

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Thr Gly Thr Asn Ser Asn Ile Gly Thr Gly 
            20                  25                  30          


Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Val 
        35                  40                  45              


Val Leu Phe Asp Asn Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 
    50                  55                  60                  


Ser Gly Ser Lys Ser Gly Thr Ser Ala Ala Leu Ala Ile Thr Gly Leu 
65                  70                  75                  80  


Gln Ala Glu Asp Glu Ala Val Tyr Tyr Cys Gln Ser Tyr Asp Lys Ser 
                85                  90                  95      


Leu Gly Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  180
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-D10 variable heavy chain

<400>  180

Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ile Phe Ser Asn Tyr 
            20                  25                  30          


Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Thr Gly Gly Ser Ser Phe Ile Asn Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Gly Gly Arg Gln Leu Ser Pro Cys Glu His Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  181
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mAb MxR-D10 variable light chain

<400>  181

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Thr Gly Gly Ser Ser Asn Ile Gly Ala Gly 
            20                  25                  30          


Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Ser Ala Pro Lys Leu 
        35                  40                  45              


Leu Met Tyr Asp Ser Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 
    50                  55                  60                  


Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 
65                  70                  75                  80  


Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Gly 
                85                  90                  95      


Leu Ser Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  182
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PIA174 CDRH1

<400>  182

Gly Gly Ser Val Ser Ser Ser Tyr Tyr 
1               5                   


<210>  183
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PIA174 CDRH2

<400>  183

Ile Tyr Tyr Ser Gly Thr Thr 
1               5           


<210>  184
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PIA174 CDRH3

<400>  184

Ala Arg Gln Val Lys Ser Gly Trp Phe Val Gln Pro Phe Asp Tyr 
1               5                   10                  15  


<210>  185
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PIA174 CDRL1

<400>  185

Gln Ala Ile Ala Asn Tyr 
1               5       


<210>  186
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PIA174 CDRL3

<400>  186

His Gln Tyr Asn Thr Tyr Pro Ile Thr 
1               5                   


<210>  187
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Reverse transcription primer for RSV

<400>  187
tccagcaaat acaccatcca ac                                                22


<210>  188
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Reverse transcription primer for HPIV3

<400>  188
ctagaaggtc aagaaaaggg aactc                                             25


<210>  189
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  RSV forward primer

<400>  189
tgactctcct gattgtggga tgata                                             25


<210>  190
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  RSV reverse primer

<400>  190
cggctgtaag accagatctg t                                                 21


<210>  191
<211>  16
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  RSV reporter

<400>  191
cccctgctgc taattt                                                       16


<210>  192
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  HPIV3 forward primer

<400>  192
cggtgacaca gtggatcaga tt                                                22


<210>  193
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  HPIV3 reverse primer

<400>  193
tgtttcaacc ataagagtta ccaagct                                           27


<210>  194
<211>  16
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  HPIV3 reporter

<400>  194
accgcatgat tgaccc                                                       16


